Should we be concerned about gastrointestinal‐related adverse events in patients with plaque psoriasis receiving secukinumab therapy? A retrospective, real‐life study

Real‐world secukinumab gastrointestinal‐related adverse events (GIRAE) data in psoriatic patients treated with secukinumab are lacking. A descriptive, retrospective study was performed by reviewing the medical records of patients who received secukinumab for plaque psoriasis for at least 1 year and who made a follow‐up visit to the dermatology clinic of “Ospedali Riuniti Umberto I” in Ancona between December 1, 2021, and March 31, 2022. The patients' medical history and clinical data were collected at T0, before treatment, and at T1, corresponding to the last follow‐up visit. Special attention was given to gastrointestinal adverse events (GIRAE). A total of 108 patients were included in the study. At baseline median PASI was 14.8 (range 2.2–27, SD 6.1), and median DLQI was 9.3 (5–16, SD 2.6). The median PASI for treated patients was 0.7 (0–3, SD 0.8; p < 0.00) 1and median DLQI was 0.3 (0–1, SD 0.5; p < 0.001). At T1 54/114 patients (50%) reached PASI100, of the other 54, 48 (88.9%) reached PASI 90 while the other six discontinued for secondary ineffectiveness. Only three patients reported a GIRAE (diarrhea), however, when screened, no IBD was found. Consistent with data in the literature, secukinumab is an effective and safe drug for the treatment of plaque psoriasis also in a real‐life experience context. There should be no concern in choosing the drug for fear of possible IBDs‐related GIRAE if there is no personal history or familiarity for IBDs.